Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 3/20 | 1.00 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 1.00 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31249645 | 1.00 | STAT3 (1.00) | STAT3CTDSP1SIRT5KDM4EKDM4C | |
| SCHEMBL12359433 | 0.97 | STAT3 (0.94) | STAT3CTDSP1SIRT5KDM4EKDM4C | |
| SCHEMBL12359466 | 0.89 | STAT3 (0.81) | STAT3CTDSP1SIRT5KDM4EKDM4C | |
| SCHEMBL2000824 | 0.87 | STAT3 (0.78) | STAT3CTDSP1SIRT5KDM4EKDM4C | |
| SCHEMBL1999611 | 0.85 | STAT3 (0.74) | STAT3CTDSP1SIRT5KDM4EKDM4C | |
| SCHEMBL25752314 | 0.83 | STAT3 (0.71) | STAT3CTDSP1SIRT5KDM4ECA12 | |
| SCHEMBL1999371 | 0.83 | STAT3 (1.00) | STAT3CTDSP1SIRT5CA12CA1 | |
| SCHEMBL28383782 | 0.82 | STAT3 (0.69) | STAT3CTDSP1SIRT5KDM4EKDM4C | |
| SCHEMBL2000416 | 0.81 | STAT3 (0.74) | STAT3CTDSP1SIRT5KDM4ECA12 | |
| SCHEMBL1998361 | 0.81 | STAT3 (0.78) | STAT3CTDSP1SIRT5KDM4ECA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251133-B1 | COMBINED THERAPY AGAINST CANCER | UNIV CATALUNYA POLITECNICA (ES) | 2025-09-24 | — | — | EP | claimed |
| US-20250114331-A1 | CONCURRENT TARGETING OF ONCOGENIC PATHWAYS TO ENHANCE CHEMOTHERAPY AND IMMUNOTHERAPY | UNIV JOHNS HOPKINS (US) | 2025-04-10 | — | — | US | claimed |
| WO-2024040220-A9 | CD83 BINDING FUSION PROTEINS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2025-02-27 | — | — | WO | claimed |
| WO-2024238399-A1 | METHODS OF MANUFACTURING ADENO-ASSOCIATED VIRAL VECTORS | SIREN BIOTECHNOLOGY, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| WO-2024220575-A2 | REGULATING DISEASE OR DISORDER CHARACTERIZED BY ESOPHAGEAL EPITHELIAL PROLIFERATION THROUGH SECRETED FRIZZLED-RELATED PROTEIN 1 (SFRP1) | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-10-24 | — | — | WO | claimed |
| US-20240307550-A1 | MODULATION OF CD46 CELL SURFACE MARKER IN BOTH ANDROGEN RECEPTOR-POSITIVE AND NEGATIVE CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-09-19 | — | — | US | claimed |
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-12 | — | — | US | claimed |
| US-20240293557-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-09-05 | — | — | US | claimed |
| CN-118006541-A | Method for dedifferentiating, transdifferentiating and rejuvenating target cells | 云南济慈再生医学研究院有限公司 | 2024-05-10 | — | — | CN | claimed |
| US-20240101699-A1 | MODULATION OF CD46 CELL SURFACE EXPRESSION AND THERAPEUTIC USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-28 | — | — | US | claimed |
| US-20230192786-A1 | STAT3 INHIBITION FOR TREATMENT AND PREVENTION OF HUMAN CORONAVIRUS INFECTION | GLG PHARMA LLC (US) | 2023-06-22 | — | — | US | claimed |
| WO-2023045266-A1 | USE OF FGFR AND RELATED SIGNALING PATHWAY INHIBITOR THEREOF IN PREPARATION OF DRUG FOR TREATING FGFR2 MUTANT TUMOR | 澳门大学 | 2023-03-30 | — | — | WO | claimed |
| US-20220249467-A1 | METHOD FOR IDENTIFYING TREATMENT OF INFECTIONS CAUSED BY PATHOGENS OF DIVERSE ORIGIN | SYSTAMEDIC INC. (US) | 2022-08-11 | — | — | US | claimed |
| US-11406707-B2 | STAT3 phosphorylation during graft-versus-host disease | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-08-09 | — | — | US | claimed |
| WO-2022150517-A1 | MODULATION OF CD46 CELL SURFACE EXPRESSION AND THERAPEUTIC USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-14 | — | — | WO | claimed |
| WO-2022150512-A1 | MODULATION OF CD46 CELL SURFACE MARKER IN BOTH ANDROGEN RECEPTOR-POSITIVE AND NEGATIVE CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-14 | — | — | WO | claimed |
| WO-2022112206-A1 | COMBINED THERAPY AGAINST CANCER | UNIVERSITAT POLITÈCNICA DE CATALUNYA (ES) | 2022-06-02 | — | — | WO | claimed |
| EP-4000600-A1 | COMBINED THERAPY AGAINST CANCER | Universitat Politècnica de Catalunya (ES) | 2022-05-25 | — | — | EP | claimed |
| EP-3993784-A1 | COMBINATION THERAPY METHODS, COMPOSITIONS AND KITS | Accure Therapeutics, S.L. (ES) | 2022-05-11 | — | — | EP | claimed |
| CN-114206329-A | Combination therapy methods, compositions and kits | 阿库尔疗法公司 | 2022-03-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299558-A1 | PROTEOLYSIS TARGETING CHIMERAS AND POLYPHARMACOLOGICAL AGENTS TARGETING BCL-2, AND METHODS OF USE THEREOF | BCL3, MCL1, BCL2 | STAT3 2639/4885CTDSP1 1680/4885SIRT5 4067/4885 |
| US-20240293557-A1 | PROTEOLYSIS TARGETING CHIMERAS AND METHODS OF USE THEREOF | MCL1, BCL3, CRBN | STAT3 1788/4885CTDSP1 1692/4885SIRT5 3507/4885 |
| US-20240307550-A1 | MODULATION OF CD46 CELL SURFACE MARKER IN BOTH ANDROGEN RECEPTOR-POSITIVE AND NEGATIVE CANCER CELLS | CD4, ITGA6, ITGB6 | STAT3 9/4885CTDSP1 4439/4885SIRT5 4747/4885 |
| US-11406707-B2 | STAT3 phosphorylation during graft-versus-host disease | STAT3, STAT1, STAT5B | STAT3 1/4885CTDSP1 160/4885SIRT5 4292/4885 |
| US-20240101699-A1 | MODULATION OF CD46 CELL SURFACE EXPRESSION AND THERAPEUTIC USE THEREOF | CD4, ITGB6, ITGA6 | STAT3 4/4885CTDSP1 4672/4885SIRT5 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.